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Abstract
Background: Netherton syndrome (NS) is a rare life-threatening syndrome caused by SPINK5 mutations leading to
a skin barrier defect and a severe atopic diathesis. NS patients are prone to bacterial infections, but the
understanding of the underlying immune deficiency is incomplete.
Results: We analyzed blood lymphocyte phenotypes and function in relation to clinical infections in
11 Finnish NS patients, aged 3 to 17 years, and healthy age-matched controls. The proportion of B cells
(CD19+) and naïve B cells (CD27−, IgD+) were high while memory B cells (CD27+) and switched memory
B cells (CD27+IgM−IgD−), crucial for the secondary response to pathogens, was below or in the lowest
quartile of the reference values in 8/11 (73%) and 9/11 (82%) patients, respectively. The proportion of
activated non-differentiated B cells (CD21low, CD38low) was below or in the lowest quartile of the reference
values in 10/11 (91%) patients. Despite normal T cell counts, the proportion of naïve CD4+ T cells was
reduced significantly and the proportion of CD8+ T central memory significantly elevated. An increased
proportion of CD57+ CD8+ T cells indicated increased differentiation potential of the T cells. The proportion
of cytotoxic NK cells was elevated in NS patients in phenotypic analysis based on CD56DIM, CD16+ and
CD27− NK cells but in functional analysis, decreased expression of CD107a/b indicated impaired cytotoxicity.
The T and NK cell phenotype seen in NS patients also significantly differed from that of age-matched atopic
dermatitis (AD) patients, indicating a distinctive profile in NS. The frequency of skin infections correlated with
the proportion of CD62L+ T cells, naïve CD4+ and CD27+ CD8+ T cells and with activated B cells. Clinically
beneficial intravenous immunoglobulin therapy (IVIG) increased naïve T cells and terminal differentiated
effector memory CD8+ cells and decreased the proportion of activated B cells and plasmablasts in three
patients studied.
Conclusions: This study shows novel quantitative and functional aberrations in several lymphocyte
subpopulations, which correlate with the frequency of infections in patients with Netherton syndrome. IVIG
therapy normalized some dysbalancies and was clinically beneficial.
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Introduction
Netherton syndrome (NS, OMIM 266500) is a severe
autosomal-recessive ichthyosiform genodermatosis with
atopic manifestations, neonatal failure to thrive and
recurrent skin infections. NS is caused by mutations in
SPINK5, encoding an epidermal serine protease inhibitor
LEKTI (lympho-epithelial Kazal-type-related inhibitor) [1].
The exact mechanism of the immunological dysfunction in
NS has not yet been fully elucidated. NS patients have a se-
lective antibody deficiency to bacterial polysaccharides [2],
elevated serum IgE and IgG4 levels, low numbers of NK
cells [3, 4] and increased levels of proinflammatory and
Th17 pathway cytokines (IL-1β, IL-12, TNFα, IL-2, IL-19)
both in serum and in skin [5, 6]. An early and broad allergic
sensitization is typical [7].
In this study, we analyzed blood lymphocyte phenotypes
and function in relation to clinical infections in a group of
11 Finnish NS patients and healthy age-matched controls.
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NS patients (n = 11, 3 female, 8 male), aged 3 to 17 years,
were recruited from the Helsinki University Hospital and
from the Seinäjoki Central Hospital, Finland. Cases V.1
and V.2, VI.1 and VI.2, and cases III.1, III.2 and III.3 are
siblings. Six age-matched healthy controls were recruited
among the elective surgery patients at the Children’s
Hospital, Helsinki University Hospital with the exception
of C1 (brother of II.2) and C2 (sister of IV.1).
Additionally, six age-matched children (1 female, 5
male), aged 2 to 7 years, were recruited from the Skin
and Allergy Hospital, HUS, out-patient ward. All had a
diagnosis of atopic dermatitis (AD) but no other
diagnosed illnesses, symptoms or diagnosed allergies at
the time of examination. One patient used desloratadine
for itching occasionally, others did not have any oral
medications. Four of the AD patients had used mild
topical corticosteroids during the past month, two had
used group II corticosteroids topically and one had used
topical tacrolimus 0.03%.
All patients from the families I, II, III, IV and V have
the same SPINK5 mutation (c.652C > T (p.Arg218X)).
Additional SPINK5 mutations were found in the families
VI (c.652C > T (p.Arg218X) and c.1220 + 1 G > C (IVS13
+ 1 G > C)) and VIII (c.1048C > T p.(Arg350*) and
c.2098G > T p.(Gly700*)). We previously reported that
patients with the same mutation seem to have a similar
clinical phenotype [7]. The samples were collected dur-
ing the time period from August 2015 to May 2017 and
additional AD patient samples in July 2018.
Infection history
Data were collected from patient records of the Helsinki
University Hospital and Seinäjoki Central Hospital, cove-
ring the time period from April 2003 to October 2017.
IVIG treatment
Patients I.1, II.1 and VIII.1 received intravenous immuno-
globulin (IVIG) therapy during the study period at a dose
of 400mg/kg/month. The protocol for II.1 was changed to
weekly subcutaneous immunoglobulin administration
(100mg/kg) after five months of IVIG therapy. I.1
received IVIG for 11months and VIII.1 for six months.
Methods
Complete blood counts (CBC), analysis of lymphocyte sub-
sets and serum immunoglobulin values were determined
according to routine and accredited laboratory methods
(http://www.huslab.fi). Mononuclear cells (MNCs) were
isolated from peripheral blood by Ficoll gradient centrifu-
gation (GE healthcare, Buckinghamshire, UK).
Lymphocyte phenotyping
B cell subsets were determined according to routine
methods (http://www.huslab.fi), and compared with
pediatric reference values [8]. Populations were identi-
fied as followed: naïve cells (CD27−IgD+IgM+), memory
cells (CD27+), non-switched cells (CD19+CD27+IgD
+IgM+), switched cells (CD19+CD27+IgD−IgM−), acti-
vated cells (CD211low, CD38low) and transitional cells
(CD38++IgM++). T cell phenotyping was performed with
FACSAria II (BD Biosciences, San Diego, CA, USA) for
CD45, CD3, CD4, CD45RA, CD62L, CD57 and CD27
surface markers and analyzed with FlowJo (Version
10.0,8r TreeStar) [9].
For NK cell phenotyping, CD45, CD3, CD14, CD19,
CD56, CD16, CD57, CD62, CD27 and CD45RA markers
were used as reported earlier (27). 50,000 CD45+ cells
were acquired with FACSAria (BD Biosciences, San
Diego, CA, USA) and analyzed with FlowJo (Version
10.0.8r, TreeStar) [9]. NK and T cell values and function
were analyzed in comparison to age-matched healthy
controls (see above). NK and T cell phenotypes were also
analyzed in comparison to AD patients.
Activation of T cells
To study the activation of T cells, MNCs were stimu-
lated with anti-CD3, anti-CD28 and anti-CD49d [9].
NK cell degranulation and cytokine secretion assays
To study the NK cell degranulation and cytokine secre-
tion capacity, fresh MNCs were stimulated with K562, a
CML cell line devoid of MHC class I expression [9].
Degranulation was measured by anti-CD107a-FITC and
anti-CD107b-FITC and cytokine secretion by anti-IFNy
and anti-TNFα and analyzed with FlowJo.
LEKTI and AIRE expression in normal thymus and tonsillar
tissue
Thymic tissue was obtained from pediatric patients under-
going thoracic surgery. Tonsillar tissue was obtained from
11 patients undergoing tonsillectomy due to either en-
larged or chronically infected tonsils. All the patients and/
or their parents gave written informed consent. All tissues
were fixed in formalin and embedded in paraffin as rou-
tinely. LEKTI and AIRE immunostainings were performed
on thymic and tonsillar tissue sections after heat-induced
epitope retrieval in citrate buffer (pH 6.0, 10min). Primary
antibodies rabbit anti-LEKTI (1:100, HPA009067,
Sigma-Aldrich, St- Louis, MO, USA) and mouse monoclo-
nal anti-AIRE (1:100, clone 6.1) [10] were diluted in 1%
BSA and applied on the sections for either 60min at room
temperature (anti-LEKTI) or overnight (anti-AIRE) at + 4
°C. The bound antibodies were visualized using Vector
Universal ImmPress kit and Vector NovaRed (Vector
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Laboratories, Burlingame, CA) and counterstained with
hematoxylin-eosin.
Statistical analysis
Statistical analyses were conducted with SPSS Statistics 24
(SPSS Inc., an IBM company). Quantitative data were
expressed as median values. Independent samples t test
was used for comparison between two groups. Correlation
between parameters was analyzed by Spearman’s rank cor-
relation coefficient. All statistical analyses were performed
with and SPSS Statistics 24 (SPSS Inc.). P < 0.05 was
considered statistically significant.
Results
Lymphocyte phenotypes and subpopulations in NS
patients
The complete blood counts and total T lymphocyte
counts of NS patients were normal except for eosinophilia
and occasional thrombocytosis. Serum immunoglobulin
values were normal apart from elevated total-IgE, IgG4
and low IgG3 levels as we have reported earlier [3]. The
proportion of CD19+ B cells was above the reference value
in 3/11 (27%) patients and within the highest quartile of
reference values in 4/11 (36%) (Fig. 1, i). The proportion
of naïve B cells (CD27, IgD+) was within the highest quar-
tile of reference values in 6/11 (55%) patients and above
reference value in one patient (Fig. 1, ii). Memory B cells
(CD27+) were within the lowest quartile of reference
values in 7/11 (64%) patients and below the reference
value in one (Fig. 1, iii). The proportion of switched mem-
ory B cells (SM, CD27+IgM−IgD−), which normally grad-
ually increases up to 4 years of age and remains stable
thereafter [11], was below the reference values in 7/11
(64%) and in the lowest quartile of reference values in two
patients (Fig. 1, iv and Fig. 2, i). This B cell population is
crucial for the secondary, T-dependent response to patho-
gens [12]. The proportion of non-switched memory B
cells (NSM; CD27+IgM+IgD+), which normally increases
during the first 5 years of life and is important for mucosal
immunity [13], varied but was below reference values in
Fig. 1 The most altered lymphocyte subtypes in Netherton syndrome. Relative proportion (%) of lymphocyte subtypes which differ in most
patients with Netherton syndrome compared with age-matched healthy controls: (i) CD19+ B cells, (ii) naïve B cells, (iii) memory B cells, (iv)
switched memory B cells, (v) non-switched memory B cells, (vi) plasmablasts, (vii) naïve CD4+ T cells, (viii) central memory CD8+ T cells, (ix)
CD8+CD27+ T cells, (x) CD56dim NK cells, (xi) CD56+CD16+ NK cells and (xii) CD56+CD27+ NK cells
Eränkö et al. Orphanet Journal of Rare Diseases          (2018) 13:213 Page 3 of 10
3/11 (27%) patients (Fig. 1, v). Pneumococcal vaccination
responses were available for three patients (I.1, II.1 and
VIII.1) and were interpreted as normal to most serotypes.
The proportion of activated non-differentiated B cells
(CD21low, CD38low) was below reference values in 6/11
(55%) patients and within the lowest quartile in 4/11
(36%) patients while that of plasmablasts (CD38++,
IgM−) was below the reference value in 5/11 (45%)
patients (Fig. 1, vi), indicating defective secretion of im-
munoglobulins [14]. The proportion of transitional B
cells (CD38++, IgM++) correlated with age: they were low
in all patients below 8 years of age (Fig. 2, ii).
To investigate the characteristics of the T and NK cells,
the cells were phenotyped with multicolor flow cytometry
prior to and after stimulation (see Additional file 1). The
proportion of naïve CD4+ T cells (CD45RA+CCR7+) was
reduced significantly (p = 0.044, Fig. 1, vii) and the pro-
portion of CD8+ T central memory (TCM) (Fig. 1, viii)
was significantly elevated (p = 0.045). Two patients had
an inverted CD4:CD8 T cell ratio. A significant
increase in the proportion of CD57+ CD8+ T cells was ob-
served (p = 0.037) and a slight decline in the proportion of
CD27+CD8+ T cells (Fig. 1, ix). Also, the proportion of T
cells (both CD4+ and CD8+) expressing the lymph node
homing receptor CD62L/L-selectin was elevated in some
patients (Fig. 3). As to the NK cells, the proportion of
both CD56dim and CD16+ cells, representing the more
cytotoxic subset and also the majority of circulating NK
cells [15, 16], was elevated in NS patients (p = 0.022 and
p = 0.016, respectively; Fig. 1, x-xi). Also the proportion of
Fig. 2 Proportions of switched and transitional B cells in different patient age groups. Altered proportion of switched (i) and transitional (ii) B cells
are found in Netherton syndrome patients. The bars indicate the reference values for each age group and the circles indicate the mean of NS
patients falling in the indicated age group. Repeated samples were taken from several patients at different ages
Fig. 3 Elevated expression of CD62L in CD4+ and CD8+ T cells of NS patients and controls. Elevated CD62L expression in CD4+ (i, p = 0.460,
patient median 93.4, control median 77.3) and in CD8+ (ii, p = 0.814, patient median 73.1, control median 65.3) T cells of NS patients and of
age-matched controls
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CD27+ NK cells was significantly reduced (p = 0.003,
Fig. 1, xii) suggesting enhanced cytotoxicity [17, 18].
Also when compared to age-matched AD patients, sta-
tistically significant alterations were seen in the T and
NK cell phenotype (see Additional file 1 for details). In
this comparison, NS patients had significantly more ma-
ture CD4+ and CD8+ T cells based on decreased propor-
tion of naïve CD4+ cells and increased proportion of
TCM, proportion of terminal differentiated effector
memory (TEMRA) and CD57+ CD4+ T cells along with
increased proportion of TCM CD8+ T cells. The im-
paired cytotoxicity and activation in NS patients were
reflected as significantly decreased expression of CD27
in CD4+ cells also in this comparison. NS patients had
also significantly more cytotoxic CD56DIM and less
CD56BRIGHT NK cells than AD patients.
Lymphocyte phenotype in family III
The three NS children of the family III showed more
mature and cytotoxic T cells, compared with the other
NS patients (Additional file 1) and had also an elevated
proportion of CD57+ NK cells (p = 0.029) reflecting the
maturity and high differentiation of the NK cells [19].
Controversially, the proportion of CD16+ NK cells
was significantly decreased (p = 0.003), reflecting
diminished cytotoxicity. The B cell profile was abnor-
mal only in III.1.
Functional capacity of peripheral blood T and NK cells in
NS patients
Upon stimulation of T cells, the production of both
IFNγ and TNFα, by both CD4+ and CD8+ T cells, was
increased compared with cells from matched healthy
controls (Fig. 4, i-ii, Additional file 1). Despite elevated
numbers of phenotypically cytotoxic NK cells, the
expression of degranulation marker CD107a/b was
significantly decreased in stimulated NK cells (Fig. 4., iii,
Additional file 1) [20]. However, granzyme B expression
was clearly increased in stimulated NK cells (CD56dim
and CD16+), excluding the family III patients in whom a
significant decrease was observed instead (Fig. 4, iv-v
and Additional file 1). Secretion of IFNγ and TNFα was
increased in all NK cells indicating that cytokine secre-
tion might compensate impaired functional cytotoxicity
(Fig. 4, vi, Additional file 1).
Fig. 4 Functional aberrations in T and NK cells of NS patients. Increased cytokine production in stimulated T cells (i, p = 0.146, patient median 8.0,
control median 4.1; and ii, p = 0.228, patient median 9.0, control median 3.4) and NK cells (vi, p = 0.199 patient median 13.6, control median 0.2),
and decreased degranulation of NK cells (iii, p = 0.088, patient median 32.5, control median 38.0) despite high expression of granzyme B (iv,
p = 0.903, patient median 81.0, control median 73.5 and v, p = 0.006, patient median without family III 82.9, control median 73.5) in stimulated NK
cells of NS patients compared with healthy controls. Outliers in panels i and v are indicated with an asterisk and a circle, respectively
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Association of infections and lymphocyte subpopulations
Typically, the NS children were hospitalized neonatally and
most (8/10, 80%) received prolonged antibiotic therapy for
skin infections (Table 1). No relevant viral or fungal infec-
tions were reported. The skin infection frequency and need
for antibiotic usage correlated with the proportion of
CD62L+ T cells, naïve CD4+ and CD27+ (intermediate
memory) CD8 cells and with activated B cells (Table 2). An
inverse correlation was found with memory B cells, NSM B
cells, CD27+ (late mature) NK cells and with CD8+ TCM
cells and CD57+ (terminally differentiated) T cells (Table 2).
Minor correlations may have been missed because of the
limited number of patients.
Immunological changes during clinical improvement
We had the opportunity to monitor the lymphocyte
subclasses during IVIG therapy in three NS patients. IVIG
has empirically proven beneficial in some NS cases [5],
although the exact mechanism of action is not known. Pa-
tients I.1, II.1 and VIII.1 underwent IVIG therapy at the
Helsinki University Hospital. S-IgG levels were normal in
all and were thus not the target of the IVIG therapy. During
therapy, the skin condition improved in I.1 and II.1 with
less erythema, pruritus and flares and better tolerance to
topical emollients. Importantly, no skin or other infections
have occurred since and the daily emollient and topical
corticosteroid use has decreased. After IVIG initiation, the
proportion of naïve CD4 and CD8 cells increased and the
proportion of TEM and TCM cells decreased (i.e. normal-
ized; Fig. 5, i-iv and Additional file 1). The proportion of
TEMRA CD8 cells rose in all three patients (Fig. 5, iii),
while TEMRA CD4 cell values decreased (Additional file
1). No major changes in the proportions of B cells, memory
B cells and SM B cells were observed (Additional file 1),
while the proportions of transitional and activated B cells
and plasmablasts decreased in all patients (Fig. 5, v-vii).
Only minor changes in the NK cell phenotypes were
observed (Additional file 1). The proportion of CD16+ cells
increased further and CD27+ cells decreased considerably
(studied in two patients) as expected [21], expanding the
difference to the healthy controls.
Clinically, the hair of I.1 and II.1 has started to grow
and thicken considerably and light microscopy revealed
that they both now have predominantly normal hair and
only infrequent trichorrhexis invaginata. For II.1 prior
allergic symptoms to pollen and animals have subsided
and a previously severe wheat allergy has subsided and
tolerance to egg and nuts has also improved. Gastro-
esophageal reflux (GER) has also cleared off and medica-
tion has been terminated. However, severe cow’s milk
allergy still prevails, and asthma symptoms have varied.
For I.1 GER symptoms initially ceased but have relapsed
to some extent. Only for patient VIII.1 (with a different
mutation) the IVIG treatment was discontinued after six
months due to lack of clear benefits. No IVIG-related
significant pre- and post-treatment changes in total IgE
levels or profiles on the ImmunoCAP ISAC microarray
were seen in patients I.1 and II.1.
LEKTI expression in relation to AIRE
The observed T cell imbalances in NS children may re-
flect a constant skin inflammation but may also be















I.1 11 1 2 1 1 1 6
II.1 10 1 2 3 2 0 8
III.1 13 1 0 2 0 1 4
III.2 10 0 0 0 0 0 0
III.3 7 0 0 0 0 0 0
IV.1 3 1 1 0 0 1 3
V.1 7 1 1 1 0 0 3
V.2 4 1 2 1 0 1 5
VI.1 6 1 1 1 2 1 6
VI.2 3 1 2 1 0 1 5
VIII.1 17 1 1 1 0 1 4
i) 0 = no; 1 = yes
ii) 0 = no, 1 = yes, for 1–1.5 year period; 2 = yes, for > 1.5 years
iii) 0 = not more frequently than usual in the age group; 1 = recurrent infections at 1–1.5 years of age, 2 = recurrent infections at > 1.5 years of age, 3 = yes, for >
1.5 years, additionally recurrent Staphylococcus aureus (PLV) abscesses
iv) 0 = no; 1 = recurrent infections at 1–1.5 years of age; 2 = frequent conjunctivitis or constant need for antibiotic eye drops
v) 0 = not; 1 = frequent external otitis or constant need for topical antibiotics; case VIII.1 had recurrent otitis media
vi) Sum of the following scores: antibiotics in infancy, antibiotic prophylaxis, bacterial skin infections, conjunctivitis and external otitis. V.1 also suffered from sepsis
after the neonatal period
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increased 0.764 0.010 0.822 0.007 0.712 0.031
CD62L expression in
CD8 T cells
increased 0.745 0.013 0.798 0.006 0.678 0.045
CD27 expression in
CD8 T cells
decreased > 0.05 0.71 0.014 > 0.05
Naïve CD4 T cells decreased 0.742 0.009 0.798 0.006 > 0.05
Activated B cells decreased > 0.05 0.692 0.006 0.613 0.020
Negative correlation
Memory B cells decreased −0.671 0.009 > 0.05 > 0.05
Non-switched B cells decreased −0.723 0.004 −0.698 0.006 −0.623 0.017
CD27 expression
in NK cells
decreased −0.788 0.004 −0.775 0.005 > 0.05
Central memory CD8
T cells
increased −0.834 0.001 −0.71 0.014 > 0.05
CD57 expression
in CD4 T cells
increased −0.822 0.004 −0.798 0.006 −0.678 0.045
CD57 expression
in CD8 T cells
increased −0.564 0.070 −0.775 0.005 > 0.05
i) see precise definitions in Additional file 1
ii) compared with age-matched healthy persons
iii) Spearman’s rank correlation coefficient,
iv) Sum of the following scores as specified in Table 1: antibiotics in infancy (0–1), antibiotic prophylaxis (0–2), bacterial skin infections (0–3), conjunctivitis (0–2)
and external otitis (0–1)
Fig. 5 Changes in lymphocyte subclasses during IVIG treatment. Most relevant changes found in lymphocyte subclasses during IVIG treatment in
NS patients. For B cell subclasses (v-viii) bars indicate the reference values for each age group and the circles indicate NS patient value falling in
the specific age group
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connected to defective LEKTI expression in medullary
thymus, where maturing T cells are exposed to
Autoimmune regulator (AIRE)-dependent self-antigen
expression. Although thymic or tonsil samples from NS
patients were not available, we looked for LEKTI expres-
sion in normal thymus and tonsil and found that LEKTI
is expressed in the Hassall’s corpuscles in close proxim-
ity to AIRE-positive medullary thymic epithelial cells
(mTEC) (Fig. 6). Interestingly, both AIRE and LEKTI
seem to have a role in the end-stage mTEC diffe-
rentiation. [22]
Discussion
Here we characterize the aberrations of several B and T
cell as well as NK cell subpopulations in a cohort of NS
patients aged 3 to 17 years. Also, T and NK cell function
was impaired although the patients did not suffer from
viral infections.
Our observation of decreased SM B cells, important for
the T cell dependent secondary response to pathogens is
similar to previous findings by Renner et al. [5, 12]. In fact,
the reduced proportion of SM B cells resembles that in
common variable immune deficiency [23]. We also found
a decrease in activated B cells and plasmablasts in NS
patients, not previously reported, and the proportion of
activated B cells positively correlated with the frequency
of bacterial skin infections.
Within the T cell population, we observed a reduction
in naïve T cells and a homeostatic expansion of effector
memory cells. In healthy newborns, peripheral blood
naïve T cell numbers are high and decline with increas-
ing age while memory T cell numbers remain more
constant. Pathogen-derived foreign antigens activate and
induce naïve T cells to undergo massive expansion and
to become effector cells [24]. The positive correlation
between naïve T cells and infections may reflect the
constant bacterial challenge on the skin.
The observed significant increase in the proportion of
CD57+ CD8+ T cells, indicates increased differentiation
of the T cells [19, 25, 26] and supports our previous
hypothesis of more mature T cells in NS patients [3].
Importantly, the T and NK cell phenotype in NS patients
differed from that observed in AD patients.
Interestingly, in addition to the skin, LEKTI is
expressed in the Hassall’s corpuscles of thymus but
LEKTI function in thymus is not known. We show that
in normal human thymus, LEKTI is often in close prox-
imity to AIRE-positive medullary thymic epithelial cells
(mTEC) and based on this and previous data in mice
[22] we anticipate LEKTI may have a role in the mTEC
environment and may influence multiple aspects of
intrathymic T cell maturation.
Also, our observation of a trend towards increased
secretion of both IFNγ and TNFα by T and NK cells is
a b
c d
Fig. 6 Expression of LEKTI and AIRE in lymphatic tissue. AIRE-expressing mTEC cells in tonsil (a), LEKTI-expressing cells in the corresponding
tonsillar area (b), AIRE-expressing cells around Hassall’s corpuscles in the thymus (c) and LEKTI expression in a corresponding thymic area (d). The
original magnification in panels is: (a) 20x, insert 100x, (b) 20x, (c) 40x and (d) 40x
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new but is in line with the previously reported ele-
vated serum TNFα values in NS patients [5]. Cytokine
production might compensate the impaired NK cell
functional cytotoxicity and activation, which was con-
firmed in this study in a larger patient cohort than
previously reported [3, 5].
Interestingly, although the family III had the same
Finnish founder mutation of SPINK5 [3], they differed
from other patients by having more mature T and NK cells
and having their B cell phenotypes mostly in reference
values. The quantity of infections in family III does not ex-
plain this difference since III.1 only suffered from frequent
infections. It is still unclear what causes the difference
between this and other families. Although we had the op-
portunity to monitor changes in the lymphocyte sub-
classes in only three NS patients under IVIG therapy, it
was of interest to note that many of the aberrant cell po-
pulations changed towards the normal proportions along
with clinical improvement. Notably, no skin infections
were observed during the IVIG therapy.
Conclusion
This study shows novel quantitative and functional aber-
rations in several lymphocyte subpopulations, which cor-
relate with the frequency of infections in patients with
Netherton syndrome.
Additional file
Additional file 1: Lymphocyte phenotypes and populations in NS, AD
and healthy control persons. The medians, p values and number of
samples for all patient and control populations are given for each
lymphocyte population (XLSX 28 kb)
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